Skip to main content

Peer Review reports

From: A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

Original Submission
11 May 2023 Submitted Original manuscript
18 May 2023 Author responded Author comments - Chunmei Bai
19 May 2023 Author responded Author comments - Chunmei Bai
Resubmission - Version 2
18 May 2023 Submitted Manuscript version 2
21 May 2023 Author responded Author comments - Chunmei Bai
Resubmission - Version 3
21 May 2023 Submitted Manuscript version 3
13 Jun 2023 Reviewed Reviewer Report
6 Aug 2023 Reviewed Reviewer Report
15 Aug 2023 Author responded Author comments - Chunmei Bai
Resubmission - Version 4
15 Aug 2023 Submitted Manuscript version 4
17 Aug 2023 Author responded Author comments - Chunmei Bai
Resubmission - Version 5
17 Aug 2023 Submitted Manuscript version 5
19 Aug 2023 Author responded Author comments - Chunmei Bai
Resubmission - Version 6
19 Aug 2023 Submitted Manuscript version 6
4 Sep 2023 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
28 Sep 2023 Editorially accepted
10 Oct 2023 Article published 10.1186/s12885-023-11464-3

You can find further information about peer review here.

Back to article page